Leads and Contacts
This article was originally published in RPM Report
Executive Summary
FDA's Safety First, SWAT and PET Committees.
You may also be interested in...
FDA Insider: Agency Looks Carefully Inside for New CDER Head
FDA’s Center for Drug Evaluation & Research still doesn’t have a permanent director. The longer the search goes on, the more likely the candidate will come from inside.
Avandia and the Commercial Impact of FDA's Credibility Gap
GlaxoSmithKline's diabetes drug Avandia survived a perilous FDA advisory committee review. The real question is whether the industry can survive the damage to FDA's credibility.
FDA Leadership Changes Reflect Budgetary, Scientific Challenges
FDA has a new chief operating officer and medical officer. The appointments reflect the challenges of a lean budget and calls for a chief scientist from the Institute of Medicine.